Drug Trial Radar · NCT07928167
Lenvatinib And Stereotactic radiothErapy With pembRolizumab in Metastatic Kidney Cancer Patients
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Aug 25, 2025
Primary completion
Jan 15, 2027
Study completion Jan 1, 2028
Sponsor
- Lead sponsor
- Kidney Cancer Research BureauAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Metastatic clear-cell renal cell carcinoma (ccRCC) is sensitive to therapy with lenvatinib and pembrolizumab. The CLEAR trial demonstrated positive outcomes even in patients with a low tumor burden. In a subset of patients with metastatic ccRCC, the presence of a low tumor burden suggests that incorporating stereotactic body radiotherapy (SBRT) into systemic therapy could be a strategy to enhance the anti-tumor response, while maintaining an acceptable toxicity profile. This study evaluates the contribution of SBRT in a subgroup of patients who have achieved stable disease while receiving lenvatinib and pembrolizumab.
Conditions
- Metastatic Renal Cell Carcinoma ( mRCC)
Interventions
LenvatinibDrug
20 mg orally once daily.
PembrolizumabDrug
200 mg intravenously every 3 weeks
Stereotactic Body Radiation Therapy (SBRT)Radiation
The dosage regimen is determined by a radiation oncologist and depends on the location of the lesion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Response of unirradiated lesions according to RECIST v1.1Time frame: Percentage of patients with response at week 12
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Republican Dispensary of Tatarstan
Kazan', Russia · Recruiting
N.N. Blokhin National Medical Research Center of Oncology
Moscow, Russia · Recruiting
STOONCO clinic
Moscow, Russia · Recruiting
Orenburg Regional Cancer Center
Orenburg, Russia · Recruiting
SBHI Leningrad Regional Clinical Hospital
Saint Petersburg, Russia · Recruiting
Cancer Center "Medical City"
Tyumen, Russia · Recruiting
Republican Clinical Oncology Dispensary
Ufa, Russia · Recruiting
"ErSpace" Radiation Therapy Center
Ulyanovsk, Russia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.